Top

Published in:

01-06-2009

Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix

Authors: Roberto Buccione, Giusi Caldieri, Inmaculada Ayala

Published in: Cancer and Metastasis Reviews | Issue 1-2/2009

Abstract

Invasive tumor–derived or transformed cells, cultured on a flat extracellular matrix substratum, extend specialized proteolytically active plasma membrane protrusions. These structures, termed invadopodia, are responsible for the focal degradation of the underlying substrate. Considerable progress has been made in recent years towards understanding the basic molecular components and regulatory circuits and the ultrastructural features of invadopodia. This has generated substantial interest in invadopodia as a paradigm to study the complex interactions between the intracellular trafficking, signal transduction and cytoskeleton regulation machineries; hopes are high that they may also represent valid biological targets to help advance the anti–cancer drug discovery process. Current knowledge will be reviewed here with an emphasis on the many open questions in invadopodia biology.

Adams, J. C. (2001). Cell-matrix contact structures. Cell Mol Life Sci, 58, 371–392.PubMed

Adams, J. C. (2002). Regulation of protrusive and contractile cell-matrix contacts. J Cell Sci, 115, 257–265.PubMed

Litjens, S. H., de Pereda, J. M., & Sonnenberg, A. (2006). Current insights into the formation and breakdown of hemidesmosomes. Trends in cell biology, 16, 376–383.PubMed

Wehrle-Haller, B., & Imhof, B. (2002). The inner lives of focal adhesions. Trends in cell biology, 12, 382–389.PubMed

Zaidel-Bar, R., Cohen, M., Addadi, L., & Geiger, B. (2004). Hierarchical assembly of cell-matrix adhesion complexes. Biochemical Society transactions, 32, 416–420.PubMed

Friedl, P., Entschladen, F., Conrad, C., Niggemann, B., & Zanker, K. S. (1998). CD4+ T lymphocytes migrating in three-dimensional collagen lattices lack focal adhesions and utilize beta1 integrin-independent strategies for polarization, interaction with collagen fibers and locomotion. European Journal of Immunology, 28, 2331–2343.PubMed

Kelly, T., Mueller, S. C., Yeh, Y., & Chen, W. T. (1994). Invadopodia promote proteolysis of a wide variety of extracellular matrix proteins. J Cell Physiol, 158, 299–308.PubMed

Mueller, S. C., & Chen, W. T. (1991). Cellular invasion into matrix beads: localization of beta 1 integrins and fibronectin to the invadopodia. J Cell Sci, 99, 213–225.PubMed

Chen, W. T. (1989). Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool, 251, 167–185.PubMed

10.

Bowden, E. T., Barth, M., Thomas, D., Glazer, R. I., & Mueller, S. C. (1999). An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation. Oncogene, 18, 4440–4449.PubMed

11.

Nakahara, H., Mueller, S. C., Nomizu, M., Yamada, Y., Yeh, Y., & Chen, W. T. (1997). Activation of beta1 integrin signaling stimulates tyrosine phosphorylation of p190RhoGAP and membrane-protrusive activities at invadopodia. J Biol Chem, 273, 9–12.

12.

Mueller, S. C., Yeh, Y., & Chen, W. T. (1992). Tyrosine phosphorylation of membrane proteins mediates cellular invasion by transformed cells. J Cell Biol, 119, 1309–1325.PubMed

13.

Monsky, W. L., Lin, C. Y., Aoyama, A., Kelly, T., Akiyama, S. K., Mueller, S. C., et al. (1994). A potential marker protease of invasiveness, seprase, is localized on invadopodia of human malignant melanoma cells. Cancer research, 54, 5702–5710.PubMed

14.

Chen, W. T. (1996). Proteases associated with invadopodia, and their role in degradation of extracellular matrix. EnzymeProtein, 49, 59–71.

15.

Baldassarre, M., Pompeo, A., Beznoussenko, G., Castaldi, C., Cortellino, S., McNiven, M. A., et al. (2003). Dynamin participates in focal extracellular matrix degradation by invasive cells. Mol Biol Cell, 14, 1074–1084.PubMed

16.

Mizutani, K., Miki, H., He, H., Maruta, H., & Takenawa, T. (2002). Essential role of neural Wiskott-Aldrich syndrome protein in podosome formation and degradation of extracellular matrix in src-transformed fibroblasts. Cancer research, 62, 669–674.PubMed

17.

Yamaguchi, H., Lorenz, M., Kempiak, S., Sarmiento, C., Coniglio, S., Symons, M., et al. (2005). Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin. J Cell Biol, 168, 441–452.PubMed

18.

Ayala, I., Baldassarre, M., Caldieri, G., & Buccione, R. (2006). Invadopodia: A guided tour. Eur J Cell Biol, 85, 159–164.PubMed

19.

Bowden, E. T., Onikoyi, E., Slack, R., Myoui, A., Yoneda, T., Yamada, K. M., et al. (2006). Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res, 312, 1240–1253.PubMed

20.

Baldassarre, M., Ayala, I., Beznoussenko, G., Giacchetti, G., Machesky, L. M., Luini, A., et al. (2006). Actin dynamics at sites of extracellular matrix degradation. Eur J Cell Biol, 85, 1217–1231.PubMed

21.

Nakahara, H., Nomizu, M., Akiyama, S. K., Yamada, Y., Yeh, Y., & Chen, W. T. (1996). A mechanism for regulation of melanoma invasion. Ligation of alpha6beta1 integrin by laminin G peptides. J Biol Chem, 271, 27221–27224.PubMed

22.

Mueller, S. C., Ghersi, G., Akiyama, S. K., Sang, Q. X., Howard, L., Pineiro-Sanchez, M., et al. (1999). A novel protease-docking function of integrin at invadopodia. J Biol Chem, 274, 24947–24952.PubMed

23.

Artym, V. V., Kindzelskii, A. L., Chen, W. T., & Petty, H. R. (2002). Molecular proximity of seprase and the urokinase-type plasminogen activator receptor on malignant melanoma cell membranes: dependence on beta1 integrins and the cytoskeleton. Carcinogenesis, 23, 1593–1601.PubMed

24.

Deryugina, E. I., Ratnikov, B., Monosov, E., Postnova, T. I., DiScipio, R., Smith, J. W., et al. (2001). MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. Exp Cell Res, 263, 209–223.PubMed

25.

Coopman, P. J., Do, M. T., Thompson, E. W., & Mueller, S. C. (1998). Phagocytosis of cross-linked gelatin matrix by human breast carcinoma cells correlates with their invasive capacity. ClinCancer research, 4, 507–515.

26.

Wyckoff, J., Wang, W., Lin, E. Y., Wang, Y., Pixley, F., Stanley, E. R., et al. (2004). A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer research, 64, 7022–7029.PubMed

27.

Yamaguchi, H., Pixley, F., & Condeelis, J. (2006). Invadopodia and podosomes in tumor invasion. Eur J Cell Biol, 85, 213–218.PubMed

28.

Hauck, C. R., Hsia, D. A., Ilic, D., & Schlaepfer, D. D. (2002). v-Src SH3-enhanced interaction with focal adhesion kinase at beta 1 integrin-containing invadopodia promotes cell invasion. J Biol Chem, 277, 12487–12490.PubMed

29.

Rykx, A., De Kimpe, L., Mikhalap, S., Vantus, T., Seufferlein, T., Vandenheede, J. R., et al. (2003). Protein kinase D: a family affair. FEBS Lett, 546, 81–86.PubMed

30.

Wang, Q. J. (2006). PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci, 27, 317–323.PubMed

31.

Tague, S. E., Muralidharan, V., & D'Souza-Schorey, C. (2004). ADP-ribosylation factor 6 regulates tumor cell invasion through the activation of the MEK/ERK signaling pathway. Proc Natl Acad Sci U S A, 101, 9671–9676.PubMed

32.

Ayala, I., Baldassarre, M., Giacchetti, G., Caldieri, G., Tete, S., Luini, A. et al. (2008). Multiple regulatory inputs converge on cortactin to control invadopodia biogenesis and extracellular matrix degradation. J Cell Sci.

33.

Kolch, W. (2005). Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol, 6, 827–837.PubMed

34.

Bokoch, G. M. (2003). Biology of the p21-activated kinases. Annual review of biochemistry, 72, 743–781.PubMed

35.

Kumar, R., Gururaj, A. E., & Barnes, C. J. (2006). p21-activated kinases in cancer. Nat Rev Cancer, 6, 459–471.PubMed

36.

Zhao, Z. S., & Manser, E. (2005). PAK and other Rho-associated kinases-effectors with surprisingly diverse mechanisms of regulation. Biochem J, 386, 201–214.PubMed

37.

Hall, A. (2005). Rho GTPases and the control of cell behaviour. Biochemical Society transactions, 33, 891–895.PubMed

38.

Heasman, S. J., & Ridley, A. J. (2008). Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat Rev Mol Cell Biol, 9, 690–701.PubMed

39.

Nobes, C. D., & Hall, A. (1995). Rho, rac and cdc42 GTPases: regulators of actin structures, cell adhesion and motility. Biochemical Society transactions, 23, 456–459.PubMed

40.

Etienne-Manneville, S. (2004). Cdc42-the centre of polarity. J Cell Sci, 117, 1291–1300.PubMed

41.

Nakahara, H., Otani, T., Sasaki, T., Miura, Y., Takai, Y., & Kogo, M. (2003). Involvement of Cdc42 and Rac small G proteins in invadopodia formation of RPMI7951 cells. Genes Cells, 8, 1019–1027.PubMed

42.

Sakurai-Yageta, M., Recchi, C., Le Dez, G., Sibarita, J. B., Daviet, L., Camonis, J., et al. (2008). The interaction of IQGAP1 with the exocyst complex is required for tumor cell invasion downstream of Cdc42 and RhoA. J Cell Biol, 181(6), 985–988.PubMed

43.

Schmidt, A., & Hall, A. (2002). Guanine nucleotide exchange factors for Rho GTPases: turning on the switch. Genes Dev, 16, 1587–1609.PubMed

44.

Zhou, K., Wang, Y., Gorski, J. L., Nomura, N., Collard, J., & Bokoch, G. M. (1998). Guanine nucleotide exchange factors regulate specificity of downstream signaling from Rac and Cdc42. J Biol Chem, 273, 16782–16786.PubMed

45.

Olson, M. F. (1996). Guanine nucleotide exchange factors for the Rho GTPases: a role in human disease? Journal of molecular medicine (Berlin, Germany), 74, 563–571.

46.

Donaldson, J. G., & Honda, A. (2005). Localization and function of Arf family GTPases. Biochemical Society transactions, 33, 639–642.PubMed

47.

Palacios, F., Price, L., Schweitzer, J., Collard, J. G., & D'Souza-Schorey, C. (2001). An essential role for ARF6-regulated membrane traffic in adherens junction turnover and epithelial cell migration. Embo J, 20, 4973–4986.PubMed

48.

Hashimoto, S., Onodera, Y., Hashimoto, A., Tanaka, M., Hamaguchi, M., Yamada, A., et al. (2004). Requirement for Arf6 in breast cancer invasive activities. Proc Natl Acad Sci U S A, 101, 6647–6652.PubMed

49.

Buccione, R., Orth, J. D., & McNiven, M. A. (2004). Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol, 5, 647–657.PubMed

50.

Gimona, M., Buccione, R., Courtneidge, S. A., & Linder, S. (2008). Assembly and biological role of podosomes and invadopodia. Curr Opin Cell Biol, 20(2), 235–241.PubMed

51.

Linder, S. (2007). The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends in cell biology, 17, 107–117.PubMed

52.

Stylli, S. S., Kaye, A. H., & Lock, P. (2008). Invadopodia: at the cutting edge of tumour invasion. J Clin Neurosci, 15, 725–737.PubMed

53.

Cao, H., Weller, S., Orth, J. D., Chen, J., Huang, B., Chen, J. L., et al. (2005). Actin and Arf1-dependent recruitment of a cortactin-dynamin complex to the Golgi regulates post-Golgi transport. Nature cell biology, 7, 483–492.PubMed

54.

Weed, S. A., & Parsons, J. T. (2001). Cortactin: coupling membrane dynamics to cortical actin assembly. Oncogene, 20, 6418–6434.PubMed

55.

McNiven, M. A., Kim, L., Krueger, E. W., Orth, J. D., Cao, H., & Wong, T. W. (2000). Regulated interactions between dynamin and the actin-binding protein cortactin modulate cell shape. J Cell Biol, 151, 187–198.PubMed

56.

Patel, A. S., Schechter, G. L., Wasilenko, W. J., & Somers, K. D. (1998). Overexpression of EMS1/cortactin in NIH3T3 fibroblasts causes increased cell motility and invasion in vitro. Oncogene, 16, 3227–3232.PubMed

57.

Bringuier, P. P., Tamimi, Y., Schuuring, E., & Schalken, J. (1996). Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. Oncogene, 12, 1747–1753.PubMed

58.

Schuuring, E. (1995). The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes—a review. Gene, 159, 83–96.PubMed

59.

Hui, R., Ball, J. R., Macmillan, R. D., Kenny, F. S., Prall, O. W., Campbell, D. H., et al. (1998). EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene, 17, 1053–1059.PubMed

60.

Uruno, T., Liu, J., Zhang, P., Fan, Y., Egile, C., Li, R., et al. (2001). Activation of Arp2/3 complex-mediated actin polymerization by cortactin. Nature cell biology, 3, 259–266.PubMed

61.

van Rossum, A. G., de Graaf, J. H., Schuuring-Scholtes, E., Kluin, P. M., Fan, Y. X., Zhan, X., et al. (2003). Alternative splicing of the actin binding domain of human cortactin affects cell migration. J Biol Chem, 278, 45672–45679.PubMed

62.

Weaver, A. M., Karginov, A. V., Kinley, A. W., Weed, S. A., Li, Y., Parsons, J. T., et al. (2001). Cortactin promotes and stabilizes Arp2/3-induced actin filament network formation. Curr Biol, 11, 370–374.PubMed

63.

Weaver, A. M., Young, M. E., Lee, W. L., & Cooper, J. A. (2003). Integration of signals to the Arp2/3 complex. Curr Opin Cell Biol, 15, 23–30.PubMed

64.

Martinez-Quiles, N., Ho, H. Y., Kirschner, M. W., Ramesh, N., & Geha, R. S. (2004). Erk/Src phosphorylation of cortactin acts as a switch on-switch off mechanism that controls its ability to activate N-WASP. Molecular and cellular biology, 24, 5269–5280.PubMed

65.

Li, Y., Tondravi, M., Liu, J., Smith, E., Haudenschild, C. C., Kaczmarek, M., & Zhan, X. (2001). Cortactin potentiates bone metastasis of breast cancer cells. Cancer research, 61, 6906–6911.PubMed

66.

Wu, H., Reynolds, A. B., Kanner, S. B., Vines, R. R., & Parsons, J. T. (1991). Identification and characterization of a novel cytoskeleton-associated pp60src substrate. Molecular and cellular biology, 11, 5113–5124.PubMed

67.

Vuori, K., & Ruoslahti, E. (1995). Tyrosine phosphorylation of p130Cas and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix. J Biol Chem, 270, 22259–22262.PubMed

68.

Zhan, X., Hu, X., Hampton, B., Burgess, W. H., Friesel, R., & Maciag, T. (1993). Murine cortactin is phosphorylated in response to fibroblast growth factor-1 on tyrosine residues late in the G1 phase of the BALB/c 3T3 cell cycle. J Biol Chem, 268, 24427–24431.PubMed

69.

Huang, C., Liu, J., Haudenschild, C. C., & Zhan, X. (1998). The role of tyrosine phosphorylation of cortactin in the locomotion of endothelial cells. J Biol Chem, 273, 25770–25776.PubMed

70.

Huang, C., Ni, Y., Wang, T., Gao, Y., Haudenschild, C. C., & Zhan, X. (1997). Down-regulation of the filamentous actin cross-linking activity of cortactin by Src-mediated tyrosine phosphorylation. J Biol Chem, 272, 13911–13915.PubMed

71.

Campbell, D. H., Sutherland, R. L., & Daly, R. J. (1999). Signaling pathways and structural domains required for phosphorylation of EMS1/cortactin. Cancer research, 59, 5376–5385.PubMed

72.

Wu, H., & Parsons, J. T. (1993). Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. J Cell Biol, 120, 1417–1426.PubMed

73.

Artym, V. V., Zhang, Y., Seillier-Moiseiwitsch, F., Yamada, K. M., & Mueller, S. C. (2006). Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer research, 66, 3034–3043.PubMed

74.

Clark, E. S., Whigham, A. S., Yarbrough, W. G., & Weaver, A. M. (2007). Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia. Cancer research, 67, 4227–4235.PubMed

75.

Krueger, E. W., Orth, J. D., Cao, H., & McNiven, M. A. (2003). A Dynamin-Cortactin-Arp2/3 Complex Mediates Actin Reorganization in Growth Factor-stimulated Cells. Mol Biol Cell, 14, 1085–1096.PubMed

76.

Schafer, D. A. (2002). Coupling actin dynamics and membrane dynamics during endocytosis. Curr Opin Cell Biol, 14, 76–81.PubMed

77.

Abram, C. L., Seals, D. F., Pass, I., Salinsky, D., Maurer, L., Roth, T. M., & Courtneidge, S. A. (2003). The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells. J Biol Chem, 278, 16844–16851.PubMed

78.

Seals, D. F., Azucena Jr., E. F., Pass, I., Tesfay, L., Gordon, R., Woodrow, M., Resau, J. H., et al. (2005). The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells. Cancer Cell, 7, 155–165.PubMed

79.

Oikawa, T., Itoh, T., & Takenawa, T. (2008). Sequential signals toward podosome formation in NIH-src cells. J Cell Biol, 182, 157–169.PubMed

80.

Blouw, B., Seals, D. F., Pass, I., Diaz, B., & Courtneidge, S. A. (2008). A role for the podosome/invadopodia scaffold protein Tks5 in tumor growth in vivo. Eur J Cell Biol, 87, 555–567.PubMed

81.

Danino, D., & Hinshaw, J. E. (2001). Dynamin family of mechanoenzymes. Curr Opin Cell Biol, 13, 454–460.PubMed

82.

McNiven, M. A., Cao, H., Pitts, K. R., & Yoon, Y. (2000). The dynamin family of mechanoenzymes: pinching in new places. Trends Biochem Sci, 25, 115–120.PubMed

83.

Hinshaw, J. E. (2000). Dynamin and Its Role in Membrane Fission. Annu Rev Cell Dev Biol, 16, 483–519.PubMed

84.

Schmid, S. L., McNiven, M. A., & De Camilli, P. (1998). Dynamin and its partners: a progress report. Curr Opin Cell Biol, 10, 504–512.PubMed

85.

Lee, E., & De Camilli, P. (2002). From the Cover: Dynamin at actin tails. Proc Natl Acad Sci U S A, 99, 161–166.PubMed

86.

Orth, J. D., Krueger, E. W., Cao, H., & McNiven, M. A. (2002). From the Cover: The large GTPase dynamin regulates actin comet formation and movement in living cells. Proc Natl Acad Sci U S A, 99, 167–172.PubMed

87.

Ochoa, G. C., Slepnev, V. I., Neff, L., Ringstad, N., Takei, K., Daniell, L., et al. (2000). A functional link between dynamin and the actin cytoskeleton at podosomes. J Cell Biol, 150, 377–389.PubMed

88.

McNiven, M. A., Baldassarre, M., & Buccione, R. (2004). The role of dynamin in the assembly and function of podosomes and invadopodia. Front Biosci, 9, 1944–1953.PubMed

89.

Shajahan, A. N., Timblin, B. K., Sandoval, R., Tiruppathi, C., Malik, A. B., & Minshall, R. D. (2004). Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J Biol Chem, 279, 20392–20400.PubMed

90.

Weaver, A. M. (2006). Invadopodia: Specialized Cell Structures for Cancer Invasion. Clin Exp Metastasis, 23(2), 97–105.PubMed

91.

Vignjevic, D., & Montagnac, G. (2008). Reorganisation of the dendritic actin network during cancer cell migration and invasion. Semin Cancer Biol, 18, 12–22.PubMed

92.

Kindzelskii, A. L., Amhadk, I., Keller, D., Zhou, M. J., Haugland, R. P., Garni-Wagner, B. A., et al. (2004). Pericellular proteolysis by leukocytes and tumor cells on substrates: focal activation and the role of urokinase-type plasminogen activator. Histochem Cell Biol, 121, 299–310.PubMed

93.

Nozaki, S., Endo, Y., Nakahara, H., Yoshizawa, K., Ohara, T., & Yamamoto, E. (2006). Targeting urokinase-type plasminogen activator and its receptor for cancer therapy. Anticancer Drugs, 17, 1109–1117.PubMed

94.

Dano, K., Behrendt, N., Hoyer-Hansen, G., Johnsen, M., Lund, L. R., Ploug, M., et al. (2005). Plasminogen activation and cancer. Thromb Haemost, 93, 676–681.PubMed

95.

Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161–174.PubMed

96.

Seiki, M. (2003). Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett, 194, 1–11.PubMed

97.

Sounni, N. E., Janssen, M., Foidart, J. M., & Noel, A. (2003). Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol, 22, 55–61.PubMed

98.

Holmbeck, K., Bianco, P., Yamada, S., & Birkedal-Hansen, H. (2004). MT1-MMP: a tethered collagenase. J Cell Physiol, 200, 11–19.PubMed

99.

Seiki, M., & Yana, I. (2003). Roles of pericellular proteolysis by membrane type-1 matrix metalloproteinase in cancer invasion and angiogenesis. Cancer Sci, 94, 569–574.PubMed

100.

Nakahara, H., Howard, L., Thompson, E. W., Sato, H., Seiki, M., Yeh, Y., et al. (1997). Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA, 94, 7959–7964.PubMed

101.

Galvez, B. G., Matias-Roman, S., Yanez-Mo, M., Sanchez-Madrid, F., & Arroyo, A. G. (2002). ECM regulates MT1-MMP localization with beta1 or alphavbeta3 integrins at distinct cell compartments modulating its internalization and activity on human endothelial cells. J Cell Biol, 159, 509–521.PubMed

102.

Baciu, P. C., Suleiman, E. A., Deryugina, E. I., & Strongin, A. Y. (2003). Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp Cell Res, 291, 167–175.PubMed

103.

Fujiwara, T., Oda, K., Yokota, S., Takatsuki, A., & Ikehara, Y. (1988). Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem, 263, 18545–18552.PubMed

104.

Steffen, A., Le Dez, G., Poincloux, R., Recchi, C., Nassoy, P., Rottner, K., et al. (2008). MT1-MMP-Dependent Invasion Is Regulated by TI-VAMP/VAMP7. Curr Biol, 18, 926–931.PubMed

105.

Gimona, M., & Buccione, R. (2006). Adhesions that mediate invasion. Int J Biochem Cell Biol, 38, 1875–1892.PubMed

106.

Linder, S., & Aepfelbacher, M. (2003). Podosomes: adhesion hot-spots of invasive cells. Trends in cell biology, 13, 376–385.PubMed

107.

Hai, C. M., Hahne, P., Harrington, E. O., & Gimona, M. (2002). Conventional protein kinase C mediates phorbol-dibutyrate-induced cytoskeletal remodeling in a7r5 smooth muscle cells. Exp Cell Res, 280, 64–74.PubMed

108.

Osiak, A. E., Zenner, G., & Linder, S. (2005). Subconfluent endothelial cells form podosomes downstream of cytokine and RhoGTPase signaling. Exp Cell Res, 307, 342–353.PubMed

109.

Spinardi, L., Rietdorf, J., Nitsch, L., Bono, M., Tacchetti, C., Way, M., et al. (2004). A dynamic podosome-like structure of epithelial cells. Exp Cell Res, 295, 360–374.PubMed

110.

Wolf, K., Friedl, P. (2008). Mapping proteolytic cancer cell-extracellular matrix interfaces. Clin Exp Metastasis.

111.

Wolf, K., Wu, Y. I., Liu, Y., Geiger, J., Tam, E., Overall, C., Stack, M. S., & Friedl, P. (2007). Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nature cell biology, 9, 893–904.PubMed

112.

Wolf, K., & Friedl, P. (2005). Functional imaging of pericellular proteolysis in cancer cell invasion. Biochimie, 87, 315–320.PubMed

113.

Jurdic, P., Saltel, F., Chabadel, A., & Destaing, O. (2006). Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol, 85, 195–202.PubMed

114.

Burgstaller, G., & Gimona, M. (2005). Podosome-mediated matrix resorption and cell motility in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol, 288, H3001–3005.PubMed

115.

Saltel, F., Destaing, O., Bard, F., Eichert, D., & Jurdic, P. (2004). Apatite-mediated actin dynamics in resorbing osteoclasts. Mol Biol Cell, 15, 5231–5241.PubMed

116.

Alexander, N. R., Branch, K. M., Parekh, A., Clark, E. S., Iwueke, I. C., Guelcher, S. A., et al. (2008). Extracellular Matrix Rigidity Promotes Invadopodia Activity. Curr Biol, 18(17), 1295–1299.PubMed

117.

Beningo, K. A., Dembo, M., & Wang, Y. L. (2004). Responses of fibroblasts to anchorage of dorsal extracellular matrix receptors. Proc Natl Acad Sci U S A, 101, 18024–18029.PubMed

118.

Li, S., Guan, J. L., & Chien, S. (2005). Biochemistry and biomechanics of cell motility. Annu Rev Biomed Eng, 7, 105–150.PubMed

Title: Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix
Authors: Roberto Buccione
Giusi Caldieri
Inmaculada Ayala
Publication date: 01-06-2009
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 1-2/2009
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-008-9176-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-2/2009

EMT, the cytoskeleton, and cancer cell invasion

Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility

Mechanics, malignancy, and metastasis: The force journey of a tumor cell

The unfolded protein response during prostate cancer development

E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer

Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer